Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | IDH2 | P48735 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30901511 | 1.00 | TSHR (0.48) | TSHRALDH1A1MAPK1IDH2MEN1 | |
| Hydrochloric Acid SCHEMBL2190046 | 0.98 | TSHR (0.47) | TSHRALDH1A1MAPK1IDH2MEN1 | |
| SCHEMBL27745521 | 0.83 | TSHR (0.45) | TSHRALDH1A1MAPK1IDH2MEN1 | |
| SCHEMBL7592350 | 0.82 | TSHR (0.52) | TSHRALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL17036644 | 0.82 | TSHR (0.44) | TSHRALDH1A1MAPK1IDH2MEN1 | |
| SCHEMBL13367373 | 0.82 | TSHR (0.48) | TSHRALDH1A1MAPK1IDH2MEN1 | |
| Hydrochloric Acid SCHEMBL11161925 | 0.82 | TSHR (0.48) | TSHRALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL4617153 | 0.80 | CETP (0.43) | TSHRALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL8979325 | 0.80 | MEN1 (0.45) | TSHRALDH1A1MAPK1IDH2MEN1 | |
| SCHEMBL15013852 | 0.80 | HTR2A (0.46) | TSHRALDH1A1MAPK1IDH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717457-A1 | PROCESS FOR PREPARATION OF ENZALUTAMIDE USING NOVEL INTERMEDIATE | Aarti Industries Limited (IN) | 2020-10-07 | — | — | EP | claimed |
| EP-0853764-A1 | COMBINATORIAL SYNTHESIS AND HIGH-THROUGHPUT SCREENING OF A REV-INHIBITING ARYLIDENEDIAMIDE ARRAY | ARQULE, INC. (US) | 1998-07-22 | — | — | EP | claimed |
| WO-1996035953-A1 | COMBINATORIAL SYNTHESIS AND HIGH-THROUGHPUT SCREENING OF A REV-INHIBITING ARYLIDENEDIAMIDE ARRAY | ARQULE, INC. (US) | 1996-11-14 | — | — | WO | claimed |
| US-20250162992-A1 | METHOD FOR PRODUCING AMIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-05-22 | — | — | US | disclosed |
| EP-4461724-A1 | METHOD FOR PRODUCING AMIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-11-13 | — | — | EP | disclosed |
| CN-118510751-A | Method for producing amide compound | 中外制药株式会社 | 2024-08-16 | — | — | CN | disclosed |
| EP-4139308-B1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023188949-A1 | SECONDARY BATTERY ELECTROLYTE AND SECONDARY BATTERY | 株式会社村田製作所 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023132352-A1 | METHOD FOR PRODUCING AMIDE COMPOUND | 中外製薬株式会社 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023116774-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | 赛诺哈勃药业（成都）有限公司 | 2023-06-29 | — | — | WO | disclosed |
| EP-3717457-B1 | PROCESS FOR PREPARATION OF ENZALUTAMIDE USING NOVEL INTERMEDIATE | AARTI INDUSTRIES LTD (IN) | 2023-06-21 | — | — | EP | disclosed |
| US-20100166655-A1 | 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-07-01 | — | — | US | disclosed |
| EP-2088861-A2 | BENZIMIDAZOLE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008051533-A2 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
| CN-100334064-C | Preparation method of N-alkylbenzene derivative | DALIAN LUYUAN PHARMACEUTICAL C (CN) | 2007-08-29 | — | — | CN | disclosed |
| EP-1818340-A1 | GLYCOPEPTIDE ANTIBIOTIC MONOMER DERIVATIVES | National University Corporation Nagoya University (JP) | 2007-08-15 | — | — | EP | disclosed |
| CN-1824644-A | Preparation method of N-alkylbenzene derivative | DALIAN LUYUAN PHARMACEUTICAL C (CN) | 2006-08-30 | — | — | CN | disclosed |
| EP-0491326-A2 | Process for the functionalization of trifluoromethylbenzenes | ISTITUTO GUIDO DONEGANI S.p.A. (IT) | 1992-06-24 | — | — | EP | disclosed |
| US-5051330-A | For image development | EASTMAN KODAK COMPANY (US) | 1991-09-24 | — | — | US | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250162992-A1 | METHOD FOR PRODUCING AMIDE COMPOUND | NAAA, NCAPH, NCAPD2 | TSHR 3232/4885ALDH1A1 1740/4885MAPK1 4021/4885 |
| US-20100166655-A1 | 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRM3 | TSHR 468/4885ALDH1A1 2815/4885MAPK1 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.